首页 > 最新文献

Current Infectious Disease Reports最新文献

英文 中文
Defining International Critical Care Pharmacist Contributions to Sepsis and Exploring Variability 定义国际重症监护药剂师对败血症的贡献并探索差异性
IF 3.1 4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-12-20 DOI: 10.1007/s11908-023-00825-5

Abstract

Purpose of Review

To define international clinical pharmacist contributions to managing sepsis in critically unwell patients and explore variation.

Recent Findings

Clinical pharmacists improve clinical outcomes and cost efficiencies. They provide pharmaceutical advice on selection, administration, plus monitoring of antimicrobials and supportive therapies. Logistical activities reduce drug administration times. Guideline production, patient/clinician education, prescribing error identification, plus therapeutic optimisation activities are also reported.

Summary

A survey incorporating semi-structured interviews identified further antimicrobial stewardship, prescribing and digital contributions to optimise sepsis management. However, disparities associated with multidisciplinary team integration and intensive care unit service provision were found. Variability was attributed to multifaceted physical, social, financial, training and education themes. Findings empower collaborations between pharmacists and stakeholders to identify and overcome contribution barriers. Strategies to mitigate barriers and enhance sepsis contributions were envisaged by reported aspirations. These emphasised the importance of professional advocacy, interprofessional education and impactful implementation research.

摘要 综述目的 界定国际临床药师在管理危重病人败血症方面的贡献并探讨差异。 最新研究结果 临床药剂师可提高临床疗效和成本效益。他们就抗菌药物和支持疗法的选择、给药和监测提供药物建议。后勤工作缩短了用药时间。此外,还报告了指南制定、患者/医师教育、处方错误识别以及治疗优化等活动。 摘要 通过一项包含半结构式访谈的调查,进一步确定了抗菌药物管理、处方和数字化对优化败血症管理的贡献。然而,我们也发现了与多学科团队整合和重症监护病房服务提供相关的差异。差异可归因于多方面的物理、社会、财务、培训和教育主题。研究结果增强了药剂师和利益相关者之间的合作,以确定并克服贡献障碍。通过报告的愿望,设想了减少障碍和加强败血症贡献的策略。这些都强调了专业宣传、跨专业教育和有影响力的实施研究的重要性。
{"title":"Defining International Critical Care Pharmacist Contributions to Sepsis and Exploring Variability","authors":"","doi":"10.1007/s11908-023-00825-5","DOIUrl":"https://doi.org/10.1007/s11908-023-00825-5","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose of Review</h3> <p>To define international clinical pharmacist contributions to managing sepsis in critically unwell patients and explore variation.</p> </span> <span> <h3>Recent Findings</h3> <p>Clinical pharmacists improve clinical outcomes and cost efficiencies. They provide pharmaceutical advice on selection, administration, plus monitoring of antimicrobials and supportive therapies. Logistical activities reduce drug administration times. Guideline production, patient/clinician education, prescribing error identification, plus therapeutic optimisation activities are also reported.</p> </span> <span> <h3>Summary</h3> <p>A survey incorporating semi-structured interviews identified further antimicrobial stewardship, prescribing and digital contributions to optimise sepsis management. However, disparities associated with multidisciplinary team integration and intensive care unit service provision were found. Variability was attributed to multifaceted physical, social, financial, training and education themes. Findings empower collaborations between pharmacists and stakeholders to identify and overcome contribution barriers. Strategies to mitigate barriers and enhance sepsis contributions were envisaged by reported aspirations. These emphasised the importance of professional advocacy, interprofessional education and impactful implementation research.</p> </span>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"203 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic Use at Hospital Discharge and Outpatient Antimicrobial Stewardship 出院时抗生素使用和门诊抗菌药物管理
IF 3.1 4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-11-20 DOI: 10.1007/s11908-023-00824-6
Mandee Noval, Colleen Burgoyne, Jacinta Chin, Kathryn Dzintars, Aileen Jimenez, Angela Perhac, Jessa Brenon

Purpose of Review

Inappropriate and unnecessary antibiotic prescriptions are common in the outpatient setting and as patients transition from inpatient to outpatient care. This review is designed to discuss effective strategies aimed to improve appropriate antibiotic use during transitions of care and in the outpatient setting for high-priority syndrome areas including acute respiratory infections (ARI), urinary tract infections (UTI), skin and soft tissue infections (SSTI), and bone and joint infections (BJI).

Recent Findings

Unlike inpatient stewardship programs, outpatient stewardship practices are currently not standardized across many healthcare systems. Since starting an outpatient ASP can be overwhelming, many programs opt to start by focusing on a smaller subset of high-priority locations or syndromes where antibiotics may be inappropriately prescribed. Numerous studies have identified effective antimicrobial stewardship strategies that can be incorporated on transitions of care and in the outpatient setting; however, a multimodal approach combining several stewardship strategies is often cited as the most effective approach. Available syndrome-specific interventions include opportunities at time of diagnosis, order entry, and post-prescription which may be tailored to meet individual program needs.

Summary

Outpatient ASP interventions targeted at diagnostic stewardship, adjustments to duration of therapy, optimization of agent selection, and avoidance of intravenous therapy remain high-priority target areas to prevent inappropriate antibiotic use.

在门诊环境中,当患者从住院转到门诊时,适当和不必要的抗生素处方很常见。本综述旨在讨论有效的策略,以提高在护理过渡期间和门诊环境中抗生素的适当使用,包括急性呼吸道感染(ARI)、尿路感染(UTI)、皮肤和软组织感染(SSTI)以及骨骼和关节感染(BJI)。最近的发现像住院病人管理项目一样,门诊病人管理实践目前在许多医疗保健系统中没有标准化。由于开始门诊ASP可能是压倒性的,许多项目选择从关注一小部分高优先位置或可能不适当开抗生素的综合征开始。许多研究已经确定了有效的抗菌药物管理策略,可纳入护理过渡和门诊环境;然而,结合几种管理策略的多式联运方法通常被认为是最有效的方法。现有的综合征特异性干预措施包括诊断时的机会、订单输入和处方后的机会,可以根据个人项目的需要进行定制。针对诊断管理、调整治疗时间、优化药物选择和避免静脉注射治疗的门诊ASP干预措施仍然是预防不当抗生素使用的重点目标领域。
{"title":"Antibiotic Use at Hospital Discharge and Outpatient Antimicrobial Stewardship","authors":"Mandee Noval, Colleen Burgoyne, Jacinta Chin, Kathryn Dzintars, Aileen Jimenez, Angela Perhac, Jessa Brenon","doi":"10.1007/s11908-023-00824-6","DOIUrl":"https://doi.org/10.1007/s11908-023-00824-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Inappropriate and unnecessary antibiotic prescriptions are common in the outpatient setting and as patients transition from inpatient to outpatient care. This review is designed to discuss effective strategies aimed to improve appropriate antibiotic use during transitions of care and in the outpatient setting for high-priority syndrome areas including acute respiratory infections (ARI), urinary tract infections (UTI), skin and soft tissue infections (SSTI), and bone and joint infections (BJI).</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Unlike inpatient stewardship programs, outpatient stewardship practices are currently not standardized across many healthcare systems. Since starting an outpatient ASP can be overwhelming, many programs opt to start by focusing on a smaller subset of high-priority locations or syndromes where antibiotics may be inappropriately prescribed. Numerous studies have identified effective antimicrobial stewardship strategies that can be incorporated on transitions of care and in the outpatient setting; however, a multimodal approach combining several stewardship strategies is often cited as the most effective approach. Available syndrome-specific interventions include opportunities at time of diagnosis, order entry, and post-prescription which may be tailored to meet individual program needs.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Outpatient ASP interventions targeted at diagnostic stewardship, adjustments to duration of therapy, optimization of agent selection, and avoidance of intravenous therapy remain high-priority target areas to prevent inappropriate antibiotic use.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"18 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138534643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex Outpatient Antimicrobial Therapy: Alternative Management Strategies and Outcomes 复杂门诊抗菌治疗:替代管理策略和结果
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-11-04 DOI: 10.1007/s11908-023-00820-w
Tucker John Guy Smith, Peter Daniels, Barry Rittmann
{"title":"Complex Outpatient Antimicrobial Therapy: Alternative Management Strategies and Outcomes","authors":"Tucker John Guy Smith, Peter Daniels, Barry Rittmann","doi":"10.1007/s11908-023-00820-w","DOIUrl":"https://doi.org/10.1007/s11908-023-00820-w","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"12 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135774059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebuilding for Tomorrow’s Outbreak: The State of Special Pathogen Preparedness in the USA in the Wake of COVID-19 为明天的疫情重建:COVID-19后美国特殊病原体防范状况
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-11-01 DOI: 10.1007/s11908-023-00821-9
Jade B. Flinn, Amy D. Britton, Jennifer Garland, Jennifer Cuzzolina, Paul D. Biddinger, Vikramjit Mukherjee, Jonathan D. Grein
{"title":"Rebuilding for Tomorrow’s Outbreak: The State of Special Pathogen Preparedness in the USA in the Wake of COVID-19","authors":"Jade B. Flinn, Amy D. Britton, Jennifer Garland, Jennifer Cuzzolina, Paul D. Biddinger, Vikramjit Mukherjee, Jonathan D. Grein","doi":"10.1007/s11908-023-00821-9","DOIUrl":"https://doi.org/10.1007/s11908-023-00821-9","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"263 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135273483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Small Step (Down) for Antibiotics, One Giant Leap for Outpatient Therapy: The Role of Oral Antibiotics in Serious Bacterial Infections 抗生素的一小步,门诊治疗的一大步:口服抗生素在严重细菌感染中的作用
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-31 DOI: 10.1007/s11908-023-00823-7
Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, Brenton C. Hall, Helen Ding
{"title":"One Small Step (Down) for Antibiotics, One Giant Leap for Outpatient Therapy: The Role of Oral Antibiotics in Serious Bacterial Infections","authors":"Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, Brenton C. Hall, Helen Ding","doi":"10.1007/s11908-023-00823-7","DOIUrl":"https://doi.org/10.1007/s11908-023-00823-7","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"41 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135870857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Opportunities and Challenges for Artificial Intelligence to Improve Sepsis Outcomes in the Paediatric Intensive Care Unit 人工智能改善儿科重症监护病房脓毒症预后的机遇与挑战
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-31 DOI: 10.1007/s11908-023-00818-4
Abdullah Tarik Aslan, Budi Permana, Patrick N. A. Harris, Kuban D. Naidoo, Michael A. Pienaar, Adam D. Irwin
Abstract Purpose of Review To describe existing applications of artificial intelligence (AI) in sepsis management and the opportunities and challenges associated with its implementation in the paediatric intensive care unit. Recent Findings Over the last decade, significant advances have occurred in the use of AI techniques, particularly in relation to medical image analysis. Increasingly, these techniques are being applied to a broad array of datasets. The availability of both structured and unstructured data from electronic health records, omics data and digital technologies (for example, portable sensors) is rapidly extending the range of applications for AI. These techniques offer the exciting potential to improve the recognition of sepsis and to help us understand the pathophysiological pathways and therapeutic targets of sepsis. Summary Although AI has great potential to improve sepsis management in children, significant challenges need to be overcome before it can be successfully implemented to change healthcare delivery.
摘要综述的目的描述人工智能(AI)在败血症管理中的现有应用及其在儿科重症监护病房实施的机遇和挑战。在过去十年中,人工智能技术的使用取得了重大进展,特别是在医学图像分析方面。越来越多地,这些技术被应用于广泛的数据集。来自电子健康记录、组学数据和数字技术(例如便携式传感器)的结构化和非结构化数据的可用性正在迅速扩大人工智能的应用范围。这些技术提供了令人兴奋的潜力,以提高对败血症的认识,并帮助我们了解败血症的病理生理途径和治疗靶点。尽管人工智能在改善儿童败血症管理方面具有巨大潜力,但在成功实施以改变医疗保健服务之前,还需要克服重大挑战。
{"title":"The Opportunities and Challenges for Artificial Intelligence to Improve Sepsis Outcomes in the Paediatric Intensive Care Unit","authors":"Abdullah Tarik Aslan, Budi Permana, Patrick N. A. Harris, Kuban D. Naidoo, Michael A. Pienaar, Adam D. Irwin","doi":"10.1007/s11908-023-00818-4","DOIUrl":"https://doi.org/10.1007/s11908-023-00818-4","url":null,"abstract":"Abstract Purpose of Review To describe existing applications of artificial intelligence (AI) in sepsis management and the opportunities and challenges associated with its implementation in the paediatric intensive care unit. Recent Findings Over the last decade, significant advances have occurred in the use of AI techniques, particularly in relation to medical image analysis. Increasingly, these techniques are being applied to a broad array of datasets. The availability of both structured and unstructured data from electronic health records, omics data and digital technologies (for example, portable sensors) is rapidly extending the range of applications for AI. These techniques offer the exciting potential to improve the recognition of sepsis and to help us understand the pathophysiological pathways and therapeutic targets of sepsis. Summary Although AI has great potential to improve sepsis management in children, significant challenges need to be overcome before it can be successfully implemented to change healthcare delivery.","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"27 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135871689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays 下一步:用新一代分子测定法研究糖尿病足感染
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-27 DOI: 10.1007/s11908-023-00822-8
Caitlin Sande, Zoë J. Boston, Lindsay R. Kalan, Meghan B. Brennan
Abstract Purpose of Review In 2019, the International Working Group on the Diabetic Foot voiced six concerns regarding the use of molecular microbiology techniques for routine diagnosis of infection complicating diabetic foot ulcers. The purpose of this review is to evaluate contemporary evidence addressing each of these concerns and describe promising avenues for continued development of molecular microbiology assays. Recent Findings Since 2019, the feasibility of conducting metagenomic and metatranscriptomic studies on diabetic foot ulcer samples has been shown. However, these preliminary studies used small samples with concerns for selection bias. We await larger-scale, longitudinal studies, potentially using the recently formed Diabetic Foot Consortium, to identify microbiome profiles associated with infection and patient outcomes. How these results would translate into a clinical diagnostic requires further clarification. Summary High-throughput molecular microbiology techniques are not yet ready for clinical adoption as first-line diagnostics. However, moving from amplicon sequencing to metagenomic and metatranscriptomic studies has the potential to significantly accelerate development of assays that might meaningfully impact patient care.
2019年,糖尿病足国际工作组就使用分子微生物技术常规诊断糖尿病足溃疡感染提出了6个问题。本综述的目的是评估解决这些问题的当代证据,并描述分子微生物学检测继续发展的有希望的途径。自2019年以来,对糖尿病足溃疡样本进行宏基因组和元转录组研究的可行性已经得到证实。然而,这些初步研究使用了小样本,考虑到选择偏差。我们等待更大规模的纵向研究,可能使用最近成立的糖尿病足联盟,以确定与感染和患者预后相关的微生物群。这些结果如何转化为临床诊断需要进一步澄清。高通量分子微生物学技术尚未准备好作为临床一线诊断。然而,从扩增子测序到宏基因组和亚转录组研究的转变有可能显著加速检测的发展,这可能会对患者护理产生有意义的影响。
{"title":"Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays","authors":"Caitlin Sande, Zoë J. Boston, Lindsay R. Kalan, Meghan B. Brennan","doi":"10.1007/s11908-023-00822-8","DOIUrl":"https://doi.org/10.1007/s11908-023-00822-8","url":null,"abstract":"Abstract Purpose of Review In 2019, the International Working Group on the Diabetic Foot voiced six concerns regarding the use of molecular microbiology techniques for routine diagnosis of infection complicating diabetic foot ulcers. The purpose of this review is to evaluate contemporary evidence addressing each of these concerns and describe promising avenues for continued development of molecular microbiology assays. Recent Findings Since 2019, the feasibility of conducting metagenomic and metatranscriptomic studies on diabetic foot ulcer samples has been shown. However, these preliminary studies used small samples with concerns for selection bias. We await larger-scale, longitudinal studies, potentially using the recently formed Diabetic Foot Consortium, to identify microbiome profiles associated with infection and patient outcomes. How these results would translate into a clinical diagnostic requires further clarification. Summary High-throughput molecular microbiology techniques are not yet ready for clinical adoption as first-line diagnostics. However, moving from amplicon sequencing to metagenomic and metatranscriptomic studies has the potential to significantly accelerate development of assays that might meaningfully impact patient care.","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"22 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should We Tap That? Aspirates and Antibiotics: An Update on Septic Bursitis 我们应该利用它吗?吸入剂和抗生素:化脓性滑囊炎的最新进展
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-27 DOI: 10.1007/s11908-023-00819-3
Rachel Weihe, Mitchell C. Birt, Wissam El Atrouni
{"title":"Should We Tap That? Aspirates and Antibiotics: An Update on Septic Bursitis","authors":"Rachel Weihe, Mitchell C. Birt, Wissam El Atrouni","doi":"10.1007/s11908-023-00819-3","DOIUrl":"https://doi.org/10.1007/s11908-023-00819-3","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"127 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136261494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is New in Augmented Renal Clearance in Septic Patients? 脓毒症患者增强肾清除率有什么新进展?
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-26 DOI: 10.1007/s11908-023-00816-6
Laura Baptista, Inês Moura, Catarina Mendes Silva, João Pedro Baptista
Abstract Purpose of Review In this narrative review encompassing relevant scientific publications regarding critically ill patients in the last 5 years, we discuss key questions regarding the concept, pathophysiology, identification, epidemiology, and implications of augmented renal clearance (ARC) in the treatment of sepsis. Recent Findings Mathematical estimates of renal function show low accuracy when evaluating renal function in the intensive care unit, jeopardizing the correct dosing of antimicrobials. The description of ARC in critically ill patients in several, distant geographical areas worldwide reveals that this condition is more frequent than anticipated. Several new risk factors have been recently reported, needing future confirmation. Pathophysiology is still largely unknown; however, intact kidney physiology, inflammatory mediators, and tubular secretion seem to play a role. Several studies have demonstrated the association between ARC and subtherapeutic levels of several β-lactams, vancomycin, and fluconazole. Lately, there have been recommendations of dosage regimen adjustments for patients with ARC, namely, through increases in total daily dose or prolonged infusion for various antimicrobials. Literature is scarce describing the influence of ARC on clinical outcomes of patients receiving antibiotics, and results are contradictory. Summary Growing body of evidence supports that measured creatinine clearance based on time-defined urine output is strongly recommended for the identification of ARC and for reliable evaluation of its prevalence and risk factors. Clinicians should be alert for the need to use off-label dosing of antimicrobials in septic patients showing ARC. Concise recommendations for antibiotic dosage regimens, based on clinical data, are still needed.
摘要:本文综述了近5年来危重症患者的相关科学文献,讨论了增强肾清除率(ARC)在脓毒症治疗中的概念、病理生理学、鉴定、流行病学和意义等关键问题。在重症监护病房评估肾功能时,肾功能的数学估计显示准确性较低,危及抗微生物药物的正确剂量。在世界上几个遥远的地理区域对危重患者中ARC的描述表明,这种情况比预期的更为频繁。最近报道了几个新的危险因素,需要进一步确认。病理生理学在很大程度上仍然未知;然而,完整的肾脏生理、炎症介质和肾小管分泌似乎发挥了作用。一些研究已经证明了ARC与几种β-内酰胺、万古霉素和氟康唑的亚治疗水平之间的关联。最近,有人建议调整ARC患者的给药方案,即增加每日总剂量或延长各种抗菌素的输注时间。文献很少描述ARC对抗生素患者临床结局的影响,结果也相互矛盾。越来越多的证据支持,强烈建议基于时间定义的尿量测量肌酐清除率,以确定ARC,并可靠地评估其患病率和危险因素。临床医生应该警惕在出现ARC的脓毒症患者中使用超说明书剂量的抗菌剂的必要性。仍然需要根据临床数据对抗生素剂量方案提出简明的建议。
{"title":"What is New in Augmented Renal Clearance in Septic Patients?","authors":"Laura Baptista, Inês Moura, Catarina Mendes Silva, João Pedro Baptista","doi":"10.1007/s11908-023-00816-6","DOIUrl":"https://doi.org/10.1007/s11908-023-00816-6","url":null,"abstract":"Abstract Purpose of Review In this narrative review encompassing relevant scientific publications regarding critically ill patients in the last 5 years, we discuss key questions regarding the concept, pathophysiology, identification, epidemiology, and implications of augmented renal clearance (ARC) in the treatment of sepsis. Recent Findings Mathematical estimates of renal function show low accuracy when evaluating renal function in the intensive care unit, jeopardizing the correct dosing of antimicrobials. The description of ARC in critically ill patients in several, distant geographical areas worldwide reveals that this condition is more frequent than anticipated. Several new risk factors have been recently reported, needing future confirmation. Pathophysiology is still largely unknown; however, intact kidney physiology, inflammatory mediators, and tubular secretion seem to play a role. Several studies have demonstrated the association between ARC and subtherapeutic levels of several β-lactams, vancomycin, and fluconazole. Lately, there have been recommendations of dosage regimen adjustments for patients with ARC, namely, through increases in total daily dose or prolonged infusion for various antimicrobials. Literature is scarce describing the influence of ARC on clinical outcomes of patients receiving antibiotics, and results are contradictory. Summary Growing body of evidence supports that measured creatinine clearance based on time-defined urine output is strongly recommended for the identification of ARC and for reliable evaluation of its prevalence and risk factors. Clinicians should be alert for the need to use off-label dosing of antimicrobials in septic patients showing ARC. Concise recommendations for antibiotic dosage regimens, based on clinical data, are still needed.","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134909304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infection Prevention in Remote or Resource-Limited Settings: Deploying Technology While Preserving the Human Touch 在远程或资源有限的环境中预防感染:在保持人性化的同时部署技术
4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2023-10-24 DOI: 10.1007/s11908-023-00814-8
Rachel Pryor, Yashasvisai Veeramasu, Gonzalo Bearman
{"title":"Infection Prevention in Remote or Resource-Limited Settings: Deploying Technology While Preserving the Human Touch","authors":"Rachel Pryor, Yashasvisai Veeramasu, Gonzalo Bearman","doi":"10.1007/s11908-023-00814-8","DOIUrl":"https://doi.org/10.1007/s11908-023-00814-8","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135273709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Infectious Disease Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1